RxDoctor Payments Data

Benjamin Ferguson, DO

Neurology · Roseville, CANPI 1871973677

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 38 payments — averaging $47.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$986
  • AbbVie$374
  • SK Life Science, Inc.$125
  • Zogenix Inc.$125
  • Pfizer$125
  • Biogen$47
  • plus $38 from 2 others

What the payments were for

  • Travel & lodging$79644%
  • Food & beverage$1,01055%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neuropace, Inc.4$986
AbbVie(2 entities)26$374
SK Life Science, Inc.1$125
Zogenix Inc.1$125
Pfizer1$125
Biogen3$47
Jazz Pharmaceuticals Inc.1$23
UCB, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,821 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$188,714
Medicare patients
322
Services billed
15,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate62$71,998
Aimovig AutoinjectorErenumab-Aooe23$22,259
Emgality PenGalcanezumab-Gnlm15$19,624
Depakote ErDivalproex Sodium12$16,472
Memantine Hcl224$10,176
Levetiracetam193$8,020
Levetiracetam ErLevetiracetam46$6,989
Lacosamide70$5,434
Carbamazepine ErCarbamazepine45$4,360
ReyvowLasmiditan Succinate11$4,159
Oxcarbazepine55$3,865
Carbidopa-LevodopaCarbidopa/Levodopa90$2,798
Gabapentin144$2,627
Donepezil Hcl176$2,286
Divalproex Sodium ErDivalproex Sodium35$1,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$125$71,99862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →